Pluvicto Radioligand Therapy Receives Dual NMPA Approvals in China
CompanyDrug

Pluvicto Radioligand Therapy Receives Dual NMPA Approvals in China

Sichuan Biokin Secures Breakthrough Therapy Designation for HER2‑Targeted ADC T‑Bren
CompanyDrug

Sichuan Biokin Secures Breakthrough Therapy Designation for HER2‑Targeted ADC T‑Bren

Shenzhen Kangtai Biological Products Launches Phase I Trial for Infant Influenza Vaccine
CompanyDrug

Shenzhen Kangtai Biological Products Launches Phase I Trial for Infant Influenza Vaccine

4D Molecular Transfers Asia‑Pacific Gene‑Therapy Rights to Otsuka for $85 M Cash
CompanyDeals

4D Molecular Transfers Asia‑Pacific Gene‑Therapy Rights to Otsuka for $85 M Cash

Novo Nordisk Reports 15 % YoY Sales Growth, Cuts Full‑Year Guidance
Company

Novo Nordisk Reports 15 % YoY Sales Growth, Cuts Full‑Year Guidance

China CDE Opens Public Comment on 100th Batch of Reference Standards for Chemical Generic Drugs
Policy / Regulatory

China CDE Opens Public Comment on 100th Batch of Reference Standards for Chemical Generic Drugs

MSD Secures Full Global Rights to MK‑8690 After $150 Million Settlement with Falk Pharma
CompanyDeals

MSD Secures Full Global Rights to MK‑8690 After $150 Million Settlement with Falk Pharma

China’s National Health Commission Launches “Silver‑Haired” Healthcare & Elderly‑Care Initiative
Policy / Regulatory

China’s National Health Commission Launches “Silver‑Haired” Healthcare & Elderly‑Care Initiative

China’s National Health Commission Issues “AI + Healthcare” Implementation Opinions – Roadmap for 24 Standardized Applications
Policy / Regulatory

China’s National Health Commission Issues “AI + Healthcare” Implementation Opinions – Roadmap for 24 Standardized Applications

Zhejiang Acea Pharma Secures Conditional NMPA Approval for Olgotrelvir Sodium Capsules – First Dual‑Target COVID‑19 Oral Antiviral in China
CompanyDrug

Zhejiang Acea Pharma Secures Conditional NMPA Approval for Olgotrelvir Sodium Capsules – First Dual‑Target COVID‑19 Oral Antiviral in China

Daiichi Sankyo’s Enhertu Wins CDE Acceptance for First‑Line HER2‑Positive Breast‑Cancer Indication in China
CompanyDrug

Daiichi Sankyo’s Enhertu Wins CDE Acceptance for First‑Line HER2‑Positive Breast‑Cancer Indication in China

Metsera Faces Escalating Bidding War as Novo Nordisk’s $10 B Offer Tops Pfizer’s Revised Proposal
CompanyDeals

Metsera Faces Escalating Bidding War as Novo Nordisk’s $10 B Offer Tops Pfizer’s Revised Proposal